Effect of obesity on vedolizumab response in inflammatory bowel disease

BACKGROUND: Vedolizumab is used in inflammatory bowel disease (IBD), administered as a non-weight-based fixed dose. A higher body mass index (BMI) is associated with lower serum vedolizumab levels, but it is unclear whether it is associated with an unfavorable response to vedolizumab. We examined th...

Descripción completa

Detalles Bibliográficos
Autores principales: Levine, Louis J., Gaidos, Jill K. J., Proctor, Deborah D., Viana, Artur V., Al-Bawardy, Badr
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hellenic Society of Gastroenterology 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9062841/
https://www.ncbi.nlm.nih.gov/pubmed/35599926
http://dx.doi.org/10.20524/aog.2022.0699

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9062841/
https://www.ncbi.nlm.nih.gov/pubmed/35599926
http://dx.doi.org/10.20524/aog.2022.0699

Ejemplares similares